Clinical Trial

ORION-10 A Placebo-Controlled, Double-Blind, Randomized Trial to Evaluate the Effect of 300 mg of Inclisiran Sodium Given as Subcutaneous Injections in Subjects With Atherosclerotic Cardiovascular Disease (ASCVD) and Elevated Low-Density Lipoprotein Cholesterol (LDL-C)

Study Status:

Contact Information:

Please contact us for more information or to learn if you are eligible to participate.

Study Purpose

The purpose is to evaluate the efficacy, safety, and tolerability of subcutaneous (SC) inclisiran injection(s) in patients with atherosclerotic cardiovascular disease and elevated LDL – C (Bad Cholesterol)

Information

Principal Investigator Mahesh Changlani, MD
Co-PI
Sponsor The Medicines Company
Type of Trial Interventional